logo
Plus   Neg
Share
Email

Bouygues' Telecom Unit Unveils Strategic Plan, Targets For FY26

Bouygues Telecom, a unit of French diversified services group Bouygues SA (BOUYY.PK), announced its new strategic plan and targets for 2026, "Ambition 2026", aiming to become the number 2 telecoms operator in mobile and a major player in fiber in France.

For fiscal 2026, the company expects to generate over 7 billion euros in sales from services; EBITDA after Leases of around 2.5 billion euros with an EBITDA after Leases margin of around 35%; and free cash flow of around 600 million euros.

In 2020, the company's sales from services are expected to be around 4.9 billion euros, EBITDA after Leases of around 1.5 billion euros, EBITDA after Leases margin of around 31%; and free cash flow of around 250 million euros.

Bouygues is holding a Capital Markets Day specifically for Bouygues Telecom. CEO Richard Viel and Deputy CEO Benoît Torloting, along with CFO Christian Lecoq, will present their vision of the telecoms market and Bouygues Telecom's medium-term strategy and outlook in the context of a new strategic plan, "Ambition 2026".

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines is adding three new flights to Croatia, Greece and Iceland, which are starting to reopen to vaccinated visitors. The move would give travelers more options for summer travel by flying direct to these countries. Last month's searches on United.com for flights to Croatia, Greece and Iceland were up 61 percent. Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies.
RELATED NEWS
Follow RTT